Clinical Trials Directory

Trials / Unknown

UnknownNCT05623930

Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver

Hepatic Enzymes and Metabolic-Risk Factors Responses to Laser Acupuncture Versus Cupping Therapy in Fatty Liver

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
35 Years – 55 Years
Healthy volunteers
Not accepted

Summary

fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)

Detailed description

In fatty liver patients,applied cupping (with scarification) will be compared, regarding its effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints

Conditions

Interventions

TypeNameDescription
DEVICElaser acupunctureIn fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
OTHERwet cuppingin this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.

Timeline

Start date
2022-10-12
Primary completion
2023-04-01
Completion
2023-04-01
First posted
2022-11-21
Last updated
2022-11-21

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05623930. Inclusion in this directory is not an endorsement.